Labopharm Reports Results for First Quarter F...(TY ----------------------------------...),Health
Navigation Links
Labopharm Reports Results for First Quarter Fiscal 2008
Date:5/8/2008
TY
-------------------------------------------------------------------------
Current
-------------------------------------------------------------------------
Accounts payable and accrued liabilities 9,451 8,719
-------------------------------------------------------------------------
Current portion of deferred revenue 4,326 4,325
-------------------------------------------------------------------------
Current portion of obligations under capital
leases 242 203
-------------------------------------------------------------------------
Total current liabilities 14,019 13,247
-------------------------------------------------------------------------
Deferred revenue 16,021 17,083
-------------------------------------------------------------------------
Obligations under capital leases 5,549 5,613
-------------------------------------------------------------------------
Long-term debt 14,422 13,647
-------------------------------------------------------------------------
Total liabilities 50,011 49,590
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Shareholders' equity
-------------------------------------------------------------------------
Share capital
-------------------------------------------------------------------------
Unlimited authorization of common shares,
voting, without par value; issued and
outstanding 56,819,663 and 56,817,963 as at
March 31, 2008 and as at December 31, 2007,
'/>"/>
| SOURCE Labopharm Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
(Date:11/21/2008)... LAKES, N.J., Nov. 21 To...edical intervention in treating 88 percent of pati... of Americans treated for a chronic condition acco...ng and 75 percent of all medical costs. A proprie... by Medco Health Solutions, Inc. (NYSE: MHS ) si...
(Date:11/21/2008)...nts in mice find running increases production of n...althDay News) -- In experiments in mice, exercise ...f brain stem cells usually seen with aging, Taiwan...ration of the brain,s ability to stave off aging a...a neurochemical that is essential for the producti...
(Date:11/21/2008)..., Nov. 21 /PRNewswire/ -- For the second year i..., McCann Healthcare Worldwide,s agency network wo...rk at the 22nd annual international RX Club Show. ...y offices won a total of 59 RX Club Awards of Exce...ng McCann Healthcare Worldwide agencies include Ca...
(Date:11/21/2008)...Nov. 21 Innerscope Research(TM), a...ializing in Emotional Response Measurement,annou... will strengthen the,company,s research and devel...es. , The three appointments, who deliver a...y Gill as Chief Financial Officer and Vice Preside...
Breaking Medicine News(10 mins):Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6Health News:Exercise Keeps the Brain Young 2Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 2Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 3Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 4Health News:Innerscope Research Strengthens Management Team With Three Executive Appointments 2[0] New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes[0] Exercise Keeps the Brain Young[0] McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008[0] Innerscope Research Strengthens Management Team With Three Executive Appointments
...orn to women with high levels of lead in their bon... babies exposed to lead from sources like old pain...the journal Pediatrics, they said this type of lea... health problem, in view of the long residence tim...
...t with medications can reduce abdominal fat in peo...rsity of Texas have been looking into the effect t...2 diabetes.// They studied 10 people with the cond... After this time body weight had, on the whole, in...
...ect people who are at high risk of suffering a str...is cheap enough to be used by opticians and GPs to...cell death due to bleeding from damaged blood vess...e in high-risk patients are available, so doctors ...
...tective substances, produced by the body in stress... TB bacteria, researchers in the UK report. Accord...ature Medicine,// these heat-shock proteins, which...cells survive stressful times and bolster the immu...
Other Medicine News:(Date:11/20/2008)..., , , , PHILADELPHIA, Nov. 20 /PRNe... today announced that the United States Food and D...val for PROMACTA(R) (eltrombopag) for the treatmen...une (idiopathic) thrombocytopenic purpura (ITP) wh...oids, immunoglobulins or splenectomy. The approval...
(Date:11/20/2008)... REINACH, Switzerland, November 20 /PRNewswire-F...hat the Anti-infective Drugs Advisory Committee of...voted 17 to 2 against the,approval of intravenous...for,the treatment of patients with complicated sk...ing those caused by methicillin-resistant Staphylo...
(Date:11/20/2008)...MERYVILLE, Calif., Nov. 20 /PRNewswire-FirstCall/ ...company will present results from the Phase 1B,cl...nced metastatic breast,cancer, BZL101, at the Soc...l,Conference in Atlanta, Georgia. The Company,s ...bstract and will be presented as a part of the Bes...
(Date:11/20/2008)...AMBRIDGE, Mass., Nov. 20 Radius He... an additional $15 million to its second instituti...vestment to $82.5 million and the total amount rai...n. All existing institutional investors participat...ic Fund and including MPM Capital, The Wellcome Tr...
Breaking Medicine Technology:FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative 8600 1Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative 8600 2Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative 8600 3Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative 8600 4Most Off Label Cancer Drug Use for Palliative Care 27727 1Most Off Label Cancer Drug Use for Palliative Care 27727 2The Beryl Companies Launches CARE Calls Program in Five Hospitals Across U S 27723 1The Beryl Companies Launches CARE Calls Program in Five Hospitals Across U S 27723 2Accuray Incorporated to Speak at Oppenheimer Healthcare Conference 27719 1Accuray Incorporated to Speak at Oppenheimer Healthcare Conference 27719 2[0] FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder[0] Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome[0] Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology[0] Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million
...ique suggests how lithium works as a,therapeutic ,...CLA have shown,that lithium, long the standard tre...of gray matter in the brains of patients with,the ...issue of the journal,Biological Psychiatry and is ...clinical neuropsychologist and assistant,professor...
... Oncology Portfolio, SOUTH SAN FRANCISCO, Calif., ...rmaceuticals, Inc. today,announced the presentatio...mall molecule inhibitors of select kinases as,pote...d other,disorders. Rigel scientists will give the ...th to 18th (see list below) at the,upcoming meetin...
Other Medicine Technology:UCLA: Lithium Builds Gray Matter in Bipolar Brains, UCLA Study,Shows 2UCLA: Lithium Builds Gray Matter in Bipolar Brains, UCLA Study,Shows 3Rigel to Present New Research Programs at AACR Meeting 2Rigel to Present New Research Programs at AACR Meeting 3Rigel to Present New Research Programs at AACR Meeting 4Rigel to Present New Research Programs at AACR Meeting 5Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays.
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays.
...e PhD System has the flexibility to accommodate EI...s with low to high volume workloads, the unique mo...g. Through networking, one to ten workstations can...ers can switch a single workstation from EIA to IF...
...idelberg Engineering GmbH, the leading developer o...nnounced the introduction of the Heidelberg Retina...ts flagship product for the assessment, diagnosis ...ssor, the HRT3 uses laser technology to produce a ...
Medicine Products:| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |